2016
383P RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity
Heong V, Koe P, Yong W, Soo R, Chee C, Wong A, Thian Y, Sundar R, Ho J, Gopinathan A, Lee S, Goh B, Tan D. 383P RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity. Annals Of Oncology 2016, 27: vi122. DOI: 10.1093/annonc/mdw368.26.Peer-Reviewed Original Research
2015
Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers.
Tan D, Pang M, Yong W, Soo R, Chee C, Thian Y, Gopinathan A, Wong A, Koe P, Sundar R, Ho J, Friedlander S, Landesman Y, Rashal T, McCauley D, Shacham S, Lee S, Goh B. Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers. Journal Of Clinical Oncology 2015, 33: 2542-2542. DOI: 10.1200/jco.2015.33.15_suppl.2542.Peer-Reviewed Original Research